Biogenvs.Incyte
BIIB vs INCY · both in Biotech & innovation, part of the Medicine, pharma & life science value chain: Innovation-driven biotech companies focused on novel treatment modalities.
Biogen is about 1.3× larger than Incyte by market cap; Incyte trades at the lower P/E (15.1 vs 37.2); year to date, Incyte leads (+29.6% vs +23.9%).
Side by side
| BIIB | INCY | |
|---|---|---|
| Market cap | $31B | $24.4B |
| Price | $220.77 | $129.72 |
| Today | +1.2% | +1.4% |
| Return YTD | +23.9% | +29.6% |
| Return 1Y | +56.6% | +50.5% |
| P/E | 37.2 | 15.1 |
| P/S | 3.1 | 4.2 |
| P/B | 1.6 | 3.8 |
Data as of 2026-08-26 · updates daily after U.S. close
The two companies
BiogenBIIB
Neurological disease is the whole focus, from multiple sclerosis to Alzheimer's, where Leqembi is partnered with Eisai.
Full BIIB profile →IncyteINCY
Jakafi in myelofibrosis and Opzelura in dermatology anchor a portfolio split between cancer and inflammation.
Full INCY profile →More BIIB & INCY comparisons
Other head-to-heads in the Biotech & innovation segment.
See where BIIB and INCY sit in the full Medicine, pharma & life science map: every segment from suppliers to end markets.Open the Life science value chain →